Dinara Samarkanova1,2,3, Luciano Rodríguez1, Joaquim Vives1,3,4, Ruth Coll1, Elisabet Tahull1, Carmen Azqueta1, Elena Valdivia1, Margarita Codinach1, Elisenda Farssac1, Jesus Gaitan5, Jose R Escudero5, Sergio Querol1,2. 1. "Banc de Sang i Teixits", Barcelona, Spain. 2. Transfusional Medicine Research Group, "Vall d'Hebron" Research Institute (VHIR), Barcelona, Spain. 3. Department of Medicine, "Universitat Autònoma de Barcelona (UAB)", Barcelona, Spain. 4. Musculoskeletal Tissue Engineering Group, "Vall d'Hebron" Research Institute (VHIR) and "Universitat Autònoma de Barcelona (UAB)", Barcelona, Spain. 5. Diabetic Foot Unit, Department of Angiology, Vascular and Endovascular Surgery, "Santa Creu i Sant Pau" Hospital, Barcelona, Spain.
Abstract
BACKGROUND: There are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, and virally safe biological material, rich in tissue regenerative factors. MATERIALS AND METHODS: We aimed to validate a bioprocess design for the production of cord blood-derived platelet concentrates (CBPC) in a public Cord Blood Bank (CBB). CBPC was defined as a product of 10±5 mL, 1,000±200×109/L total platelets, free of erythrocytes and leukocytes. A total of 300 CB units were centrifuged in two steps to enrich for platelets, in compliance with Good Manufacturing Practice. The samples were tested for the degree of platelet activation present, and the levels of growth factor were analysed to evaluate their potential function. CBPC were then activated after thawing with 10% calcium gluconate to generate platelet gels (CBPG) to treat patients with diabetic foot ulcers. RESULTS: After processing, 84% of the products fulfilled the acceptance criteria. Final products contained 1,017±149×106 platelets/mL in 10±3mL of plasma. Platelet recovery was 50±9%. The methods described here ensure depletion of white and red blood cells down to a residual concentration of 0.2±0.1×106/mL and 0.03±0.02×106/mL, respectively. Platelets showed low levels of activation during processing, but were significantly activated after thawing, as indicated by an increase in CD62p expression. The growth factors EGF, VEGF, bFGF, PDGF AB/BB and TGF-β1 were at concentrations of 1,706±123 pg/mL; 1,602±227 pg/mL; 314±26 pg/mL; 30±1.5 ng/mL; 24±2 ng/mL (mean±standard error of mean), respectively. For clinical evaluation, a total of 21 CBPG were applied in 3 patients, with no reported adverse events and improvement of ulcers in all of them. DISCUSSION: We designed and validated a highly reproducible, closed system method to manufacture high quality CBPC suitable for clinical applications using CB units not suitable for transplantation in a public CBB.
BACKGROUND: There are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, and virally safe biological material, rich in tissue regenerative factors. MATERIALS AND METHODS: We aimed to validate a bioprocess design for the production of cord blood-derived platelet concentrates (CBPC) in a public Cord Blood Bank (CBB). CBPC was defined as a product of 10±5 mL, 1,000±200×109/L total platelets, free of erythrocytes and leukocytes. A total of 300 CB units were centrifuged in two steps to enrich for platelets, in compliance with Good Manufacturing Practice. The samples were tested for the degree of platelet activation present, and the levels of growth factor were analysed to evaluate their potential function. CBPC were then activated after thawing with 10% calcium gluconate to generate platelet gels (CBPG) to treat patients with diabetic foot ulcers. RESULTS: After processing, 84% of the products fulfilled the acceptance criteria. Final products contained 1,017±149×106 platelets/mL in 10±3mL of plasma. Platelet recovery was 50±9%. The methods described here ensure depletion of white and red blood cells down to a residual concentration of 0.2±0.1×106/mL and 0.03±0.02×106/mL, respectively. Platelets showed low levels of activation during processing, but were significantly activated after thawing, as indicated by an increase in CD62p expression. The growth factors EGF, VEGF, bFGF, PDGF AB/BB and TGF-β1 were at concentrations of 1,706±123 pg/mL; 1,602±227 pg/mL; 314±26 pg/mL; 30±1.5 ng/mL; 24±2 ng/mL (mean±standard error of mean), respectively. For clinical evaluation, a total of 21 CBPG were applied in 3 patients, with no reported adverse events and improvement of ulcers in all of them. DISCUSSION: We designed and validated a highly reproducible, closed system method to manufacture high quality CBPC suitable for clinical applications using CB units not suitable for transplantation in a public CBB.
Authors: Yu A Romanov; E E Balashova; N E Volgina; N V Kabaeva; T N Dugina; G T Sukhikh Journal: Bull Exp Biol Med Date: 2017-02-27 Impact factor: 0.804
Authors: Eva Stokhuijzen; Johanna Maria Koornneef; Benjamin Nota; Bart Laurens van den Eshof; Floris Pieter Joachim van Alphen; Maartje van den Biggelaar; Carmen van der Zwaan; Carlijn Kuijk; Koen Mertens; Karin Fijnvandraat; Alexander Benjamin Meijer Journal: J Proteome Res Date: 2017-08-30 Impact factor: 4.466
Authors: E Gluckman; V Rocha; A Boyer-Chammard; F Locatelli; W Arcese; R Pasquini; J Ortega; G Souillet; E Ferreira; J P Laporte; M Fernandez; C Chastang Journal: N Engl J Med Date: 1997-08-07 Impact factor: 91.245
Authors: K Akhundov; G Pietramaggiori; L Waselle; S Darwiche; S Guerid; C Scaletta; N Hirt-Burri; L A Applegate; W V Raffoul Journal: Ann Burns Fire Disasters Date: 2012-12-31